Mono-(2-ethylhexyl) phthalate stimulates basal steroidogenesis by a cAMP-independent mechanism in mouse gonadal cells of both sexes

David Gunnarsson, Per Leffler1, Emelie Ekwurtzel, Gunilla Martinsson, Kui Liu2 and Gunnar Selstam

Department of Molecular Biology, Umeå University, S-901 87 Umeå, Sweden, 1Division of CBRN Defence and Security, Swedish Defence Research Agency, Department of Threat Assessment, Cementvägen 20, S-901 82 Umeå, Sweden and 2Department of Medical Biochemistry and Biophysics, Umeå University, S-901 87 Umeå, Sweden

Correspondence should be addressed to G Selstam; Email: gunnar.selstam@molbiol.umu.se

Abstract

Phthalates are widely used as plasticizers in a number of daily-life products. In this study, we investigated the influence of mono-(2-ethylhexyl) phthalate (MEHP), the active metabolite of the frequently used plasticizer di-(2-ethylhexyl) phthalate (DEHP), on gonadal steroidogenesis in vitro. MEHP (25–100 µM) stimulated basal steroid synthesis in a concentration-dependent manner in immortalized mouse Leydig tumor cells (MLTC-1). The stimulatory effect was also detected in KK-1 granulosa tumor cells. MEHP exposure did not influence cAMP or StAR protein levels and induced a gene expression profile of key steroidogenic proteins different from the one induced by human chorionic gonadotropin (hCG). Simultaneous treatment with MEHP and a p450scc inhibitor (aminoglutethimide) indicated that MEHP exerts its main stimulatory effect prior to pregnenolone formation. MEHP (10–100 µM) up-regulated hormone-sensitive lipase and 3-hydroxy-3-methylglutaryl coenzyme A reductase, suggesting that MEHP increases the amount of cholesterol available for steroidogenesis. Our data suggest that MEHP, besides its known inhibitory effect on hCG action, can directly stimulate gonadal steroidogenesis in both sexes through a cAMP- and StAR-independent mechanism. The anti-steroidogenic effect of DEHP has been proposed to cause developmental disorders such as hypospadias and cryptorchidism, whereas a stimulation of steroid synthesis may prematurely initiate the onset of puberty and theoretically affect the hypothalamic–pituitary–gonadal axis.

Reproduction (2008) 135 693–703

Introduction

The prevalence of reproductive disorders such as hypospadias, cryptorchidism, and testicular cancer has increased during the last decades in several Western countries (Lottrup et al. 2006). These disorders are hypothesized to be manifestations of the same underlying prenatal disturbance, the testicular dysgenesis syndrome (TDS; Skakkebaek et al. 2001). Genetic as well as environmental factors are believed to be involved in the etiology of TDS. Among environmental factors, phthalates have been given special focus since exposure is almost unavoidable and phthalates cause a TDS-like phenotype in laboratory animals (Virtanen et al. 2005).

Phthalates are a group of industrial chemicals commonly used as plasticizers in a variety of consumer products, such as polyvinyl chloride (PVC) floors, toys, car interiors, and medical devices. Di-(2-ethylhexyl) phthalate (DEHP) is one of the most frequently used phthalates, and in Western Europe it accounts for ~30% of all plasticizer usage. It is considered to have a low acute toxicity in several species, including man (Rhodes et al. 1986). However, at high doses, DEHP has been shown to cause developmental and/or reproductive toxicity in a number of mammalian species including rodents (Parks et al. 2000). Lower doses of DEHP appear to give rise to more subtle effects. At doses equivalent to the exposure level in the general population, DEHP can increase testosterone concentrations and reduce sperm production, through a yet unknown mechanism (Andrade et al. 2006). In addition, recent studies indicate a possible relationship between human phthalate exposure and altered development in both males and females (Colon et al. 2000, Swan et al. 2005).

Since DEHP is not chemically bound to the plastic polymer it is continuously released into the atmosphere, food products, or directly into body fluids from medical devices (Koch et al. 2006). The general population is exposed to DEHP primarily through inhalation and ingestion (Silva et al. 2006). The major metabolite of DEHP, mono-(2-ethylhexyl) phthalate (MEHP), is thought to be the active agent in testicular (Sjoberg et al. 1986) as well as ovarian toxicity (Davis et al. 1994b). When ingested orally,
DEHP is rapidly hydrolyzed by intestinal lipases to MEHP, which is readily absorbed from the gut (Ljungvall et al. 2004). In the airways, DEHP is absorbed as the parent compound and thereafter metabolized to MEHP (Shea 2003). Serum MEHP levels are generally low in the population (50th percentile 4 ng/ml), but markedly higher levels of exposure occur in, for example, patients undergoing intensive care (Kato et al. 2004). Infants are particularly exposed and plasma MEHP levels as high as 15.1 μg/ml (≈54 μM) have been recorded (Sjoberg et al. 1985).

Previous in vitro studies of phthalate exposure have focused on the effects on human chorionic gonadotropin (hCG)- or 8-Br-cAMP-induced steroidogenesis. Alterations in basal steroid synthesis may be equally important and the objective of this study was to investigate the influence of MEHP on basal steroidogenesis and elucidate mechanisms in male as well as female gonadal cells. For this purpose, immortalized mouse Leydig (MLTC-1) and granulosa (KK-1) tumor cells were used.

Results

Stimulation of basal steroidogenesis

In order to examine the influence of MEHP on basal Leydig cell steroidogenesis, MLTC-1 cells were exposed to MEHP, in the concentration range 10–100 μM, for 24 h. At the end of exposure, the media were collected and assayed for progesterone and testosterone by dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA). As displayed in Fig. 1A, MEHP stimulated progesterone synthesis in a concentration-dependent manner, with 25 μM being the lowest concentration that caused a significant increase (1.7-fold). Maximal stimulation was observed after exposure to 100 μM MEHP, where the synthesis was enhanced more than 6-fold as compared with untreated control cells.

MEHP at a concentration of 25 μM was used to analyze the time course of the stimulatory effect. As can be seen in Fig. 2, the first time point at which a statistically significant stimulation could be detected was 12 h. At this time point, MEHP-exposed cells had ~1.2-fold higher production of progesterone than control cells. Testosterone synthesis was also elevated by MEHP in the same concentration range (25–100 μM), as shown in Fig. 1B. However, the stimulation of testosterone production was less pronounced and reached a maximum of 1.7-fold above control values at 75 and 100 μM MEHP. To investigate whether MEHP influenced steroidogenesis in granulosa cells, progesterone was measured also in media collected from KK-1 cells exposed to 100 μM MEHP for 24 h (Fig. 3). MEHP was found to enhance progesterone production with ~120%.

Lack of effect on cAMP

Figure 4 shows intracellular cAMP levels in MLTC-1 and KK-1 cells exposed to 100 μM for 1 h. No significant alteration in cAMP levels was observed in either MLTC-1 or KK-1 cells after MEHP exposure. Positive controls,
i.e., MLTC-1 cells treated with 50 μg/l hCG and KK-1 cells treated with 10 μM forskolin, exhibited markedly elevated cAMP levels.

Gene expression profiles induced by MEHP and hCG

To compare the gene expression profile induced by MEHP with the one induced by hCG, mRNA expression of three key steroidogenic proteins was analyzed by rt-Q-RT-PCR. Figure 5A presents the mRNA expression of StAR, p450scc, and p450c17 after MEHP exposure (100 μM for 24 h), whereas the expression of the same genes after hCG treatment (10 μg/l for 4 h) is shown in Fig 5B. Although MEHP strongly stimulated steroidogenesis, its influence on the analyzed genes differed noticeably from that of hCG. The hCG treatment up-regulated the expression of StAR (2.3-fold) and p450c17 (2.2-fold). MEHP exposure reduced the expression of StAR, p450scc, and p450c17 by 35, 30, and 50% respectively.

Effect of p450scc inhibition

In order to determine the site of action of MEHP, MLTC-1 cells were exposed to 100 μM MEHP for 24 h in the presence or the absence of a p450scc inhibitor (aminoglutethimide). The cells exposed to 100 μM MEHP without aminoglutethimide had a 4.1-fold higher progesterone synthesis than control cells, whereas the progesterone production in cells exposed to 100 μM MEHP together with 400 μM aminoglutethimide was only 1.9-fold higher than in controls (Table 1). Hence, the primary site of action appears to be prior to the formation of pregnenolone in the mitochondrion. The finding that MEHP stimulated steroidogenesis to some degree also in the presence of aminoglutethimide suggests a second minor site of action, subsequent to pregnenolone formation.
Lack of effect on STAR

The expression of STAR protein in MLTC-1 cells exposed to 100 μM MEHP for 24 h was detected by Western blot (Fig. 6, upper panel). STAR protein expression was quantified with the software Quantity One and normalized to β-actin (Fig. 6, lower panel). As can be seen in the figure, MEHP exposure did not change the STAR protein level.

Up-regulation of HSL and HMG-CoA reductase

Since steroidogenesis is dependent on the amount of available cholesterol, the mRNA expression of hormone-sensitive lipase (HSL, Lipe) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (Hmgcr) was measured. HSL as well as HMG-CoA reductase was up-regulated in MLTC-1 cells exposed to MEHP (Fig. 7). The lowest concentration of MEHP that resulted in increased expression of HSL (1.9-fold) and HMG-CoA reductase (1.7-fold) was 10 μM. The concentration 100 μM had a stronger effect, whereas the lowest concentration (1 μM) did not influence the expression of HSL and HMG-CoA reductase.

Inhibition of hCG-induced steroidogenesis

Progesterone synthesis in MLTC-1 cells exposed to 100 μM MEHP and thereafter stimulated with 10 μg/l hCG was measured. HPLC analysis showed that the mean ± S.E.M. (n=6 per group) progesterone concentration for MLTC-1 cells exposed to 100 μM MEHP and thereafter stimulated with 10 μg/l hCG was 14.7 ± 1.8. In contrast, the mean ± S.E.M. (n=6 per group) progesterone concentration for MLTC-1 cells exposed to 100 μM MEHP and thereafter stimulated with 10 μg/l hCG was 0.09 ± 0.02. The degree of increase after MEHP exposure is indicated in the last column. *Significantly different (P<0.001) from controls not treated with MEHP. †Significantly different (P<0.001) from the corresponding (-) aminoglutethimide group.

Table 1 Influence of 100 μM mono-(2-ethylhexyl) phthalate (MEHP) on basal progesterone synthesis in the mouse Leydig tumor cell line MLTC-1 cells, in the presence or the absence of 400 μM aminoglutethimide (n=6 per group).

<table>
<thead>
<tr>
<th>Progesterone (pg/ml/10^6 cells)</th>
<th>Control</th>
<th>100 μM MEHP</th>
<th>Fold change compared with controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aminoglutethimide (-)</td>
<td>73.1 ± 10.5</td>
<td>300 ± 23.9*</td>
<td>4.1</td>
</tr>
<tr>
<td>Aminoglutethimide (+)</td>
<td>6.79 ± 1.43†</td>
<td>12.8 ± 1.14**</td>
<td>1.9</td>
</tr>
</tbody>
</table>

The cells were seeded at a density of 6 × 10^4 cells in 24-well plates and allowed to adhere overnight. The cells were then treated with either 100 μM MEHP or DMSO (control) for 24 h. Aminoglutethimide was added to a final concentration of 400 μM in the (+) aminoglutethimide exposure medium. Data are presented as mean ± S.E.M. The degree of increase after MEHP exposure is indicated in the last column. *Significantly different (P<0.001) from controls not treated with MEHP. †Significantly different (P<0.001) from the corresponding (-) aminoglutethimide group.

Figure 6 Expression of STAR protein in MLTC-1 cells exposed to 100 μM MEHP or DMSO (controls) for 24 h. Ten micrograms of total protein were used to detect STAR protein levels by western blot. STAR protein expression was quantified with the software Quantity One, normalized to β-actin, and presented as mean ± S.E.M. (lower panel).

Figure 7 Effects of MEHP on the mRNA expression of (A) hormone-sensitive lipase (HSL) and (B) 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in MLTC-1 cells. The cells were seeded at a density of 7 × 10^5 cells/flask in 50 ml flasks and allowed to adhere overnight. Thereafter, the cells were exposed to 1–100 μM MEHP (n=4) for 24 h. Total RNA was isolated and mRNA levels determined with real-time quantitative RT PCR (rt-Q-RT-PCR). The mRNA expression of HSL and HMG-CoA reductase was normalized to β-actin. Data are presented as mean ± S.E.M. *P<0.05, **P<0.01 and ***P<0.001 respectively, versus values for controls.

Figure 8 Influence of MEHP on hCG-stimulated progesterone synthesis in MLTC-1 cells (n=4 per group). The cells were seeded at a density of 1 × 10^5 cells/flask in 160 ml flasks and allowed to adhere overnight. The cells were then exposed to 100 μM MEHP or DMSO (control) for 24 h. At the end of incubation, the medium was aspirated and steroidogenesis induced by hCG-treatment (10 μg/l) for 4 h. Thereafter, the medium was collected and assayed for progesterone. Data are presented as mean ± S.E.M. ***P<0.001 versus values for controls.
hCG for 4 h is shown in Fig. 8. In sharp contrast to its stimulatory effect on basal steroidogenesis, MEHP significantly inhibited hCG-induced progesterone synthesis. Progesterone production was reduced by ∼60% after MEHP exposure, when compared with hCG-stimulated control cells.

**Discussion**

This study shows that MEHP can stimulate basal steroidogenesis in gonadal cells of both sexes. We demonstrate that MEHP increases basal steroid synthesis in a concentration-dependent manner by a cAMP-independent mechanism. MEHP was found to stimulate steroidogenesis in Leydig as well as granulosa cells. This is the first article describing a stimulatory effect in female gonadal cells. Gene expression data revealed that an increased amount of cholesterol available for steroidogenesis is the likely underlying mechanism. These findings contribute to the understanding of the reproductive and developmental toxicology of phthalates.

Alterations in steroidogenesis are of great importance since sex hormones regulate fetal development as well as the onset of puberty. Male sexual differentiation and development is critically dependent on Leydig cell testosterone secretion. Disruption of androgen synthesis (or signaling) adversely affects prenatal as well as postnatal sexual development in the male. Complete inactivation of either the luteinizing hormone (LH) receptor (Gromoll et al. 2002) or the androgen receptor (Brown et al. 1990) gives rise to a female phenotype in human XY males. Development of female internal and external genitalia does not require gonadal hormones and thus the female fetus is less vulnerable to in utero exposure. Pubertal development, on the other hand, is dependent on sex hormones in both boys and girls. Female mice overexpressing hCG, thereby producing high progesterone levels, are known to develop precocious puberty and infertility (Rulli et al. 2002). Hence, sex differentiation and development can be affected by increased as well as decreased steroidogenesis.

Recent studies indicate that phthalate exposure can alter steroid hormone-dependent processes in both the male and the female. Swan et al. (2005) discovered reduced anogenital distance and impaired testicular descent in boys of mothers with elevated phthalate exposure during pregnancy. Later in life, pubertal development is tightly regulated by the gonadotropin-releasing hormone pulse generator that stimulates pituitary and gonadal hormone synthesis. Thus, a stimulation of basal steroidogenesis by phthalates may possibly result in precocious puberty. Consistent with this, Colon et al. (2000) found significantly elevated serum levels of DEHP, di-n-butyl phthalate (DBP), and MEHP in 68% of girls in Puerto Rico with premature breast development. In addition to the findings in humans, it is well known that phthalates cause a number of reproductive and developmental disorders in animal models. In the male, intrauterine phthalate exposure affects reproductive tract development in several ways. DEHP and DBP, which also have endocrine disrupting potential, cause hypospadias, cryptorchidism, and malformations of epidiymis, prostate, and testes (Mahood et al. 2005, Foster 2006). This TDS-like phenotype appears to be caused by an alteration in fetal testosterone synthesis during a time period when androgens regulate development (Fisher et al. 2003, Foster 2006). A sharp decrease in testicular testosterone production has been shown to precede the above-mentioned malformations (Foster 2006). In female mice, DEHP (2 g/kg) decreases estradiol synthesis, prolongs the estrus cycle, and causes anovulation (Davis et al. 1994a). Using cultured granulosa cells, it has been demonstrated that MEHP is the active metabolite in reducing estradiol production (Lovekamp & Davis 2001). Although the previously mentioned study by Swan et al. (2005) indicates that human developmental disturbances are associated with phthalate exposure, it should be emphasized that no conclusive evidence exists of a relationship between phthalate exposure and TDS in humans.

Previous in vitro studies to determine the mechanisms of action of phthalates have focused on LH receptor-mediated steroidogenesis, induced either by hCG or 8-Br-cAMP (Davis et al. 1994b, Dees et al. 2001, Wang et al. 2006). LH is indeed required for postnatal sexual development, but its role in prenatal differentiation has been shown to be less crucial (Ahtiainen et al. 2007). Male fetuses show normal differentiation also in the absence of LH-induced testosterone synthesis (Weiss et al. 1992, El-Gehani et al. 1998, Zhang et al. 2001). In rodents a number of non-gonadotropic factors are able to substitute for LH, whereas in humans hCG is thought to have this role (Ahtiainen et al. 2007). For this reason, alterations in basal steroidogenesis may be as important as the previously described effects on LH receptor-mediated steroid synthesis. However, since the regulation is likely to differ between species, applying animal data to humans should be done with some caution.

Our finding that MEHP markedly enhances steroid synthesis in Leydig as well as granulosa cells is not congruent with most in utero studies. However, most investigators have used DEHP/DBP doses high enough to ensure a high prevalence of reproductive malformations; most available data are based on high-dose (above 100 mg/kg per day) exposure (Parks et al. 2000, Shultz et al. 2001). At doses relevant to human exposure, DEHP appears to cause more subtle effects, including enhanced testosterone secretion. Andrade and collaborators recently discovered that in utero and lactational exposure to 0.045 mg/kg per day DEHP significantly increased serum testosterone concentrations and reduced daily sperm production in the male offspring (Andrade et al. 2006). This dose is equivalent to the daily exposure level of DEHP in Korean women (Koo & Lee 2005) and only threefold higher than the estimated daily intake in the general German population (Koch et al. 2003). Thus,
the effects described in this article resemble alterations associated with low-dose rather than high-dose exposure. Interestingly, during the preparation of this article, Ge et al. (2007) established that MEHP stimulates testosterone synthesis in primary rat Leydig cells. It is therefore likely that the mechanistic findings from cell lines presented in this article reflect the situation in primary steroidogenic cells. In addition, Ge et al. (2007) discovered a biphasic effect of DEHP on pubertal development, with low-dose treatment advancing the onset of puberty.

The discovery that phthalates influence testicular function at doses equivalent to the exposure level in the general population is particularly interesting since the incidence of male reproductive disorders is increasing. Hypospadias, cryptorchidism, and testicular cancer have become more frequent during the last 50 years (Bay et al. 2006). At present, genetic as well as environmental factors are believed to be involved in the development of these disorders. In 2004, Boisen et al. (2004) discovered a significantly higher prevalence of cryptorchidism among Danish infants as compared with 40 years earlier, indicating the importance of environmental factors. Genetic factors, on the other hand, appear to play a role in the development of testicular cancer. Black & Hispanic men are known to have a significantly lower incidence of testicular cancer than white men residing in the same area (Spitz et al. 1986). However, it should be emphasized that extrapolating in vitro and in vivo data to humans must be done with caution. Instead, mechanisms discovered in animal models should serve as hypotheses for future research.

Data from rt-Q-RT-PCR in MLTC-1 cells are in agreement with our finding that the stimulation of steroidogenesis occurs independently of cAMP. Among the proteins involved in steroidogenesis, StAR and p450c17 appears to be the ones most tightly regulated by cAMP. Anakwe & Payne (1987) demonstrated that removal of cAMP from the culture medium totally abolished the synthesis of p450c17 in mouse Leydig cells after 48 h. StAR, which mediates the rate-limiting step in steroidogenesis, is acutely regulated in adrenal as well as gonadal steroidogenic cells through cAMP-mediated signaling (Manna et al. 2003). In our study hCG alone significantly increased, as expected, the mRNA expression of StAR and p450c17. MEHP exposure, on the other hand, resulted in significantly reduced StAR and p450c17 mRNA levels. In contrast to StAR and p450c17, the synthesis and activity of p450scc and 3β-hydroxysteroid dehydrogenase (3βHSD) remain largely unaffected by cAMP withdrawal (Wing et al. 1984, Anakwe & Payne 1987). We found that MEHP exposure caused a significant decrement of p450scc mRNA expression. In conclusion, the mRNA expression profiles differ markedly between hCG- and MEHP-treated cells.

Since the analyzed genes in the steroidogenic pathway were down-regulated after MEHP exposure, it is reasonable to believe that MEHP exerted its stimulatory effect primarily through other mechanisms. The unaffected cAMP levels together with the severely reduced stimulation of progesterone production after treatment with a p450scc inhibitor (aminoglutethimide) suggest a site of action subsequent to cAMP but prior to pregnenolone formation. An earlier study described increased StAR mRNA and protein expressions after MBP exposure (Wang et al. 2006). Our data, on the other hand, do not support a role for StAR in the stimulation of steroidogenesis. Another possible mechanism is activation of protein kinase C (PKC), which has been shown to enhance basal steroid synthesis (Brunswig et al. 1986, Nikula & Huhtaniemi 1989) but has an opposite effect on hCG-stimulated synthesis (Benhaim et al. 1987). These effects resemble those seen after MEHP exposure in our study. However, co-treatment with a PKC inhibitor (GF109203X) did not reduce the stimulatory effect of MEHP (data not shown), thus excluding PKC activation as the underlying mechanism.

The time course of stimulation of progesterone synthesis together with the lack of effect on second messenger signaling indicates that altered gene expression underlies the effect of MEHP on steroidogenesis. Sex steroid synthesis depends not only on steroidogenic enzymes and transport proteins, but also on cholesterol availability. In this study, MEHP up-regulated two genes involved in cholesterol metabolism and mobilization, HSL (Lipe), and HMG-CoA reductase (Hmgcr). An elevated expression of HSL and HMG-CoA reductase was detected after exposure to 10 and 100 μM, but not 1 μM, MEHP. Hence, these genes were up-regulated at MEHP concentrations that increased steroidogenesis. HSL is a widely distributed enzyme with a capacity to hydrolyze several lipid substrates, including triacylglycerols and cholesteryl esters, whereas HMG-CoA reductase is the rate-limiting enzyme in cholesterol synthesis (Yeaman 2004). These enzymatic activities are important for testosterone synthesis, and reduced hydrolysis of cholesteryl esters as well as decreased HMG-CoA reductase activity has been associated with decreased steroidogenesis in the aging rat testis (Liao et al. 1993). In contrast, Leydig cells with a high testosterone production display high HMG-CoA reductase activity and strong HSL expression (Hou et al. 1990, Rao et al. 2003). In steroidogenic cells HSL hydrolyzes cholesteryl esters to free cholesterol that is subsequently transported into the mitochondria for further conversion to pregnenolone (Rao et al. 2003). As shown by Rao et al. (2003), rodent Leydig cell lines with a high level of steroid synthesis show strong HSL expression, whereas HSL is only weakly expressed in cells with a low level of synthesis. From guinea pigs it is known that HSL expression and enzymatic activity are positively correlated with serum testosterone concentrations (Kabbaj et al. 2001). HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate,
which is considered to be the major point of regulation in the synthesis of cholesterol. In Leydig as well as granulosa cells, hCG/cAMP treatment enhances HMG-CoA reductase activity and causes a concomitant increase in steroid production (Hou et al. 1990, Medicherla et al. 1996).

The relative importance of cholesterol mobilization, intracellular synthesis, and uptake varies between different steroidogenic cells. Leydig cell steroidogenesis appears to rely primarily on hydrolysis of cholesteryl esters and endogenous cholesterol synthesis, whereas adrenal cells are highly dependent on lipoprotein uptake (Travert et al. 2000). However, Leydig cells also have the capacity for lipoprotein uptake and if testosterone synthesis is blocked by a HMG-CoA reductase inhibitor, addition of HDL fully overcomes the inhibitory effect (Travert et al. 2000). The flexibility to use different mechanisms to increase the amount of cholesterol available for steroid synthesis may also explain why testosterone production was found to be normal in HSL−/− mice (Osuga et al. 2000). To conclude, our results strongly suggest that MEHP stimulates steroidogenesis by increasing the amount of cholesterol available for steroid biosynthesis. The complexity of cholesterol metabolism in steroidogenic cells implies that future studies should investigate in more detail the respective role of cholesterol synthesis, mobilization, and transport in MEHP-induced stimulation of steroidogenesis.

In this study, the mechanism whereby MEHP up-regulates HSL and HMG-CoA reductase was not established. However, it is known that MEHP and a number of other industrial chemicals activate peroxisome proliferator-activated receptors (PPARs). PPARs belong to the nuclear hormone receptor superfamily and regulate, by binding to target gene peroxisome proliferator response elements, a wide range of genes involved in lipid metabolism (Maloney & Waxman 1999, Le Jossic-Corcos et al. 2004, Feige et al. 2007). Of the three known isofoms, PPARα, PPARβ, and PPARγ, MEHP has been found to activate the α and γ isoforms (Venkata et al. 2006). Both these isofoms are expressed in Leydig as well as granulosa cells, and MEHP-induced activation of these transcription factors may explain the increased HSL and HMG-CoA reductase expression found in this study (Schultz et al. 1999, Lovekamp-Swan et al. 2003, Borch et al. 2006). The PPARα activation has been related to increased HMG-CoA reductase mRNA expression and cholesterogenesis, whereas the activation of PPARγ increases the expression of HSL (Le Jossic-Corcos et al. 2004, Feige et al. 2007). In favor of this hypothesis, known PPARγ ligands increase granulosa cell progesterone synthesis by a mechanism described to be independent of p450scx and 3BHSD (Froment et al. 2003). The effects of MEHP exposure on the liver and ovary have been attributed to PPAR activation (Lovekamp-Swan et al. 2003, Corton & Lapinskas 2005, Lapinskas et al. 2005), but the role of PPAR signaling in testicular toxicity is not that clear.

Studies of PPARα null mice have revealed that some but not all testicular effects seen after DEHP exposure are due to PPARα activation (Ward et al. 1998), whereas the role of PPARγ has not yet been properly evaluated. MEHP acting as a PPAR ligand may also explain why this phthalate reduced steroid synthesis under hCG-induced conditions. PPARγ ligands have been shown to interfere with cAMP signaling by inhibiting the phosphorylation of cAMP-activated transcription factors and their binding to the DNA. Han et al. (2005) discovered that PPARγ ligands reduced the DNA-binding activities of cAMP response element-binding protein (CREB) and Sp1, both of which are crucial for the transcriptional regulation of steroidogenic genes. Transcription factors CREB and Sp1 positively regulate StAR, p450scx, and p450c17, all of which were down-regulated by MEHP in this study (Lund et al. 1990, Venepally & Waterman 1995, Manna et al. 2003, Zhang & Veldhuis 2004, Sher et al. 2007).

Hence, activation of PPAR may be the mechanism underlying the opposite effects of MEHP on steroidogenesis. According to this hypothesis, MEHP stimulates basal steroidogenesis by activating transcription factors belonging to the PPAR family. PPAR activation induces the expression of genes involved in cholesterol metabolism, thereby increasing the substrate for steroid synthesis. On the other hand, the activation of PPAR transcription factors also alters the DNA-binding capacity of cAMP-activated transcription factors causing a down-regulation of steroidogenic genes. As a consequence, the stimulatory effect of hCG is reduced in MEHP-exposed cells. Further experiments should be designed to test this hypothesis.

Since it is difficult to state from in vitro and in vivo animal data, future studies should address whether phthalate exposure is correlated with the increased frequency of reproductive disorders in the human population. Environmental factors have been suggested to influence the risk of precocious puberty (Teilmann et al. 2006), and to assess the impact of phthalate-stimulated steroidogenesis is an important task. In view of the fact that phthalates can both stimulate steroidogenesis in the male and female gonadal cells (this study) and inhibit gonadotropin-induced steroidogenesis, phthalate research should be expanded to include work on other hormones of importance for male sexual development.

Materials and Methods

Cell culture

The mouse Leydig tumor cell line (MLTC-1) was purchased from American Type Culture Collection (Rockville, MD, USA), whereas the granulosa tumor cell line, KK-1, was a generous gift from Dr Ilpo Huhtaniemi (Imperial College, London). MLTC-1 cells were maintained in Waymouth’s medium supplemented with 4.5% heat-inactivated fetal bovine serum (Sigma) and 9% heat-inactivated horse serum (Sigma), supplemented with 4.5% heat-inactivated fetal bovine serum (Sigma) and 9% heat-inactivated horse serum (Sigma),
Upplands Väsby, Sweden) respectively. The hCG-stimulated DELFIA Progesterone and Testosterone kits (Perkin-Elmer, Waltham, MA, USA) were used for the determination of hormone content. Progesterone and testosterone concentrations were determined by time-resolved fluoroimmunoassay, using a commercially available cAMP kit (Perkin-Elmer).

**Western blot analysis of 30 kDa StAR**

MLTC-1 cells were seeded at a density of 1 × 10⁶ cells/160 ml flask and allowed to adhere overnight. The cells were then exposed to 100 μM MEHP for 24 h. At the end of exposure, the cells were trypsinized, resuspended in Waymouth’s medium supplemented with 0.1% BSA, and pelleted by centrifugation at 400 × g for 10 min. The cell pellets were placed at −20 °C for 60 min. Thereafter, the cells were lysed by sonication on ice for 20 min in 50 μl ARF lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 0.1% Tween-20 before use supplemented with 100 mM phenylmethylsulphonyl fluoride, 1 mM β-glycerophosphate, 0.4 M NaF, 100 mM NaVO₃ and 1 tablet of Roche Mini Complete). Lysates were centrifuged at 20,000 × g for 10 min at 4 °C and supernatants were stored at −80 °C until analysis.

The protein content of supernatants was determined using the method of Bradford (1976). From each sample 10 μg protein were solubilized in loading buffer (65 mM Tris–HCl, pH 6.8, 5% SDS, 5% β-mercaptoethanol, 10% glycerol, and 0.01% bromphenol blue) and separated on a 12% SDS-PAGE mini-gel (Mini Protean II, Bio-Rad). Proteins were thereafter electrophoretically transferred overnight to a polyvinyl difluoride (PVDF) membrane (Bio-Rad) using a transfer buffer containing 25 mM Tris, 192 mM glycine, and 20% methanol. The membrane was washed three times (5 min each) in distilled water and preincubated in Tris-buffered saline (TBS) with 0.1% Tween-20 and 5% non-fat dried milk for 2 h. The membrane was then incubated for 1 h with rabbit anti-mouse StAR antibody, generated against a glutathione S-transferase fusion protein from full-length StAR cDNA (Hales et al. 2000). The PVDF membrane was washed three times (15 min each) in TBS with 0.5% Tween-20, followed by three washes (1 min each) in TBS with 0.1% Tween-20 (TBST). The membrane was then washed as described previously. β-Actin was used as an internal control and a HRP-conjugated β-actin antibody (cat nr: ab20272, Abcam, Cambridge, UK) was used to measure its expression. The specific signal was revealed using Immobilon Western HRP Substrate Peroxide Solution (Millipore Corporation, Bedford, MA, USA), according to the manufacturer’s description. Finally, the membranes were exposed to a high-performance autoradiography film (Amersham Biosciences). Autoradiograms were quantified using the software Quantity One (Bio-Rad) and StAR protein expression was normalized to β-actin.
Isolation of total RNA and real-time quantitative RT PCR (rt-Q-RT-PCR)

MLTC-1 cells were seeded at a density 1 × 10^6 cells/160 ml flask or 7 × 10^5 cells/50 ml flask (depending on experiment) and exposed to 1–100 µM MEHP (depending on experiment) for 24 h. Total RNA was isolated using TRIzol LS Reagent (Invitrogen) according to the manufacturer’s description and resuspended in 10 mM Tris–HCl, pH 8.0. RNA concentrations were determined spectrophotometrically and 50 ng was used for rt-Q-RT-PCR. Sequences were obtained from Ensembl Genome Browser and primers for STAR, p450scx, p450c17, HSL (Lipe), HMG-CoA reductase (Hmgcr), and β-actin were ordered from DNA Technology (Aarhus, Denmark). In order to avoid amplification of genomic DNA, the primers were designed to be in intron spanning. Primer sequences are available upon request. rt-Q-RT-PCR was carried out with iScript One-Step RT-PCR kit with SYBR GREEN (Bio-Rad). Melt curves were inspected to ensure that one single product had been amplified in each reaction. mRNA expression of STAR, p450scx, p450c17, HSL, and HMG-CoA reductase was normalized to β-actin. To determine which genes are induced by cAMP signaling in MLTC-1 cells, expression levels of STAR, p450scx, and p450c17 were measured in cells stimulated with hCG for 4 h.

Statistical analyses

Statistical differences between groups were determined using a two-tailed unpaired Student’s t-test. Data are presented as mean ± S.E.M.

Acknowledgements

We sincerely thank Dr Ilpo Huhtaniemi (Imperial College, London, UK) and Dr Dale Buchanan Hales (University of Illinois at Chicago, Chicago, USA) for their generous gifts of KK-1 cells and StAR antibody respectively. This study was supported by the Faculty of Science and Technology, Umeå University, Umeå, Sweden. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

References


Foster PM 2006 Disruption of reproductive development in male rat offspring following in utero exposure to phthalate esters. International Journal of Andrology 29 140–147 (discussion 181–145).


Lovekamp SW, Tjuten AM & Davis BJ 2003 Dual activation of PPARalpha and PPARgamma by mono-(2-ethylhexyl) phthalate in rat ovarian granulosa cells. Molecular and Cellular Endocrinology 201 133–141.


Skakkebaek NE, Rajpert-De Meyts E & Main KM 2001 Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Environmental Health Perspectives 113 106–116.


Zhang FP, Poutanen M, Wilbertz J & Huhtaniemi I 2001 Normal prenatal but arrested postnatal sexual development of luteinizing hormone receptor knockout (LuRKO) mice. Molecular Endocrinology 15 172–183.

Received 11 October 2007
First decision 27 November 2007
Revised manuscript received 26 January 2008
Accepted 7 February 2008